UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 97

Sortiert nach

Association between FAS polymorphism and prostate cancer development

Prostate cancer and prostatic diseases, 2008-03, Vol.11 (1), p.94-98

2008

Link zum Volltext

Verfügbarkeit prüfen

Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility

The pharmacogenomics journal, 2009-10, Vol.9 (5), p.341-346

2009

Link zum Volltext

Verfügbarkeit prüfen

International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial

Journal of clinical oncology, 2011-06, Vol.29 (16), p.2171-2177

2011

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer

Annals of oncology, 2009-07, Vol.20 (7), p.1264-1269

2009

Link zum Volltext

Verfügbarkeit prüfen

The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration

European journal of cancer (1990), 2014-01, Vol.50 (2), p.359-365

2014

Link zum Volltext

Verfügbarkeit prüfen

Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)

European urology, 2008-05, Vol.53 (5), p.941-949

2008

Link zum Volltext

Verfügbarkeit prüfen

563 Effects of prior use of statins in a phase 3 study of intermittent monotherapy versus continuous combined androgen deprivation

European urology supplements : official journal of the European Association of Urology, 2015-04, Vol.14 (2), p.e563-e563

2015

Link zum Volltext

Verfügbarkeit prüfen

Zoledronic acid in patients with adenocarcinoma of the prostate M1

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.14623-14623

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase II screening study of an LHRH analog, dexamethasone and somatostatin analog versus LHRH analogue with dexamethasone in HRPC

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.15579-15579

2007

Link zum Volltext

Verfügbarkeit prüfen

Zolendronic acid in patients with adenocarcinoma of the prostate M1

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.4777-4777

2005

Link zum Volltext

Verfügbarkeit prüfen

Fas-670 polymorphism and prostate cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.21028-21028

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase III study of intermitent monotherapy versus continuous combined androgen deprivation

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5125-5125

2007

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of quality-of-life side effects and duration of therapy in a phase III study of intermittent monotherapy versus continuous combined androgen deprivation

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5064-5064

2008

Link zum Volltext

Verfügbarkeit prüfen

Five years survival and risk of death in a phase III study of intermmittent monotherapy versus continuous combined androgen deprivation

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.16034-16034

2008

Link zum Volltext

Verfügbarkeit prüfen

Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study

European urology, 1997, Vol.31 (3), p.272

1997

Link zum Volltext

Verfügbarkeit prüfen

Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group

Oncology, 2003-01, Vol.65 Suppl 1, p.24-28

2003

Link zum Volltext

Verfügbarkeit prüfen

Intermittent hormone therapy: Not a standard for many urologists and oncologists. Why?

European urology supplements : official journal of the European Association of Urology, 2016, Vol.15 (2), p.62-62a

Calais Da Silva, F

2016

Link zum Volltext

Verfügbarkeit prüfen

380 Combined analysis of SNPs in IL-6/IL-6R pathway predict prostate cancer aggressiveness and development of resistance to hormonal castration

European journal of cancer supplements, 2010, Vol.8 (5), p.97-97

2010

Link zum Volltext

Verfügbarkeit prüfen

96 Adiponectin functional polymorphisms and haplotype are associated with prostate cancer aggressiveness and to hormonal castration resistance

European journal of cancer supplements, 2010, Vol.8 (5), p.25-25

2010

Link zum Volltext

Verfügbarkeit prüfen

97 Non-synonym leptin receptor genetic variants, prostate cancer susceptibility and aggressiveness

European journal of cancer supplements, 2010, Vol.8 (5), p.25-26

2010

Link zum Volltext

Verfügbarkeit prüfen

89 Influence of functional genetic variants of TGFβ1/TGFβR2 pathway in prostate cancer development

European journal of cancer supplements, 2010, Vol.8 (5), p.23-24

2010

Link zum Volltext

Verfügbarkeit prüfen

Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer : a subanalysis of EORTC trial 30853

Cancer, 1990-09, Vol.66 (5), p.1009-1016

1990

Link zum Volltext

Verfügbarkeit prüfen

1101 Prostate cancer and apoptosis: An insight of FAS-670A/G polymorphism role in tumor development

European journal of cancer supplements, 2009, Vol.7 (2), p.115-115

2009

Link zum Volltext

Verfügbarkeit prüfen

Zoledronic acid in M1 patients: HRPC versus hormonal sensitive

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.16120-16120

2008

Link zum Volltext

Verfügbarkeit prüfen

843 Phase III study of intermittent monotherapy versus continuous combined androgen deprivation

European urology supplements : official journal of the European Association of Urology, 2016-03, Vol.15 (3), p.e843-e843a

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(83)

Publikationsform

Artikel
(97)

Sprache

Englisch
(97)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(32)
Life Sciences & Biomedicine
(29)
Male
(29)
Science & Technology
(29)
Biological And Medical Sciences
(20)
Medical Sciences
(20)
Urology
(19)
Middle Aged
(18)
Aged
(17)
Urology & Nephrology
(17)
Hematology, Oncology And Palliative Medicine
(13)
Nephrology. Urinary Tract Diseases
(11)
Oncology
(11)
Quality Of Life
(11)
Tumors Of The Urinary System
(11)
Urinary Tract. Prostate Gland
(11)
Prostatic Neoplasms - Pathology
(10)
Aged, 80 And Over
(9)
Chemotherapy
(9)
Pharmacology. Drug Treatments
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Association between FAS polymorphism and prostate cancer development

Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility

International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer

The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration

Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)

563 Effects of prior use of statins in a phase 3 study of intermittent monotherapy versus continuous combined androgen deprivation

Zoledronic acid in patients with adenocarcinoma of the prostate M1

Phase II screening study of an LHRH analog, dexamethasone and somatostatin analog versus LHRH analogue with dexamethasone in HRPC

Zolendronic acid in patients with adenocarcinoma of the prostate M1

Fas-670 polymorphism and prostate cancer

Phase III study of intermitent monotherapy versus continuous combined androgen deprivation

Evaluation of quality-of-life side effects and duration of therapy in a phase III study of intermittent monotherapy versus continuous combined androgen deprivation

Five years survival and risk of death in a phase III study of intermmittent monotherapy versus continuous combined androgen deprivation

Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study

Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group

Intermittent hormone therapy: Not a standard for many urologists and oncologists. Why?

380 Combined analysis of SNPs in IL-6/IL-6R pathway predict prostate cancer aggressiveness and development of resistance to hormonal castration

96 Adiponectin functional polymorphisms and haplotype are associated with prostate cancer aggressiveness and to hormonal castration resistance

97 Non-synonym leptin receptor genetic variants, prostate cancer susceptibility and aggressiveness

89 Influence of functional genetic variants of TGFβ1/TGFβR2 pathway in prostate cancer development

Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer : a subanalysis of EORTC trial 30853

1101 Prostate cancer and apoptosis: An insight of FAS-670A/G polymorphism role in tumor development

Zoledronic acid in M1 patients: HRPC versus hormonal sensitive

843 Phase III study of intermittent monotherapy versus continuous combined androgen deprivation

Suchergebnisse filtern